Clinical Trials
Riverside is here for you during the COVID-19 outbreak.

For more information, please click here.

Celgene ACE-536-MDS-002

A phase 3, open-label, randomized study to compare the efficacy and safety of Luspatercept (ACE-536) versus Epoetin Alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naive subjects who require red blood cell transfusions. (COMMANDS)

Celgene ACE-536-MDS-002: A phase 3, open-label, randomized study to compare the efficacy and safety of Luspatercept (ACE-536) versus Epoetin Alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naive subjects who require red blood cell transfusions. (COMMANDS)

 

The main purpose of this study is to see if people with anemia due to MDS will experience a more decreased need for regular blood transfusions if they take luspatercept plus best supportive care compared to epoetin alfa plus best supportive care. They safety of luspatercept compared to the safety of epoetin alfa will also be evaluated in this study.

Principal Investigator

William MacLaughlin, MD

Contact

Ora Mae Jackson, RN, OCN
757-534-5565
[email protected]

Locations

Peninsula Cancer Institute
12100 Warwick Blvd, Suite 201
Newport News, VA 23601

Peninsula Cancer Institute
120 King's Way, Suite 3100
Williamsburg, VA 23185

Peninsula Cancer Institute
7544-B Medical Drive
Gloucester, VA 23061

Cancer Specialists of Tidewater
110-E Wimbledon Square
Chesapeake, VA 23320

Cancer Specialists of Tidewater
1200 First Colonial Road
Virginia Beach, VA 23454

Cancer Specialists of Tidewater
5839 Harbourview Blvd. Suite 100
Suffolk, VA 23435

Status

Recruiting

Category

Oncology

Study #

NCT01688011